search
Back to results

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

Primary Purpose

Dental Caries

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
C16G2
Placebo
Sponsored by
Armata Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Dental Caries

Eligibility Criteria

12 Years - 75 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Adolescent Safety Only Cohort: Males and females, 12-17 years of age, inclusive, at the time the Assent and Informed Consent Form is signed. Study Arms 1 & 2: Males and females, 12-75 years of age, inclusive, at the time the Assent and/or Informed Consent Form is signed
  2. Female subjects of childbearing potential, defined as not surgically sterile or at least two (2) years postmenopausal, must agree to use one of the following forms of contraception from screening through the last study visit: hormonal (oral, implant, or injection) begun >30 days prior to screening; barrier (condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive options may also include abstinence, relationship with same sex partner or partner who has had a vasectomy at least six (6) months prior to the screening visit
  3. Male subjects only: willing to use contraception or abstain from sexual activity beginning with the first exposure to study drug and continuing until discharged from the study due to completion or Early Termination
  4. Healthy, as determined by the Investigator, based on medical and dental history, concurrent illnesses, laboratory results, concomitant medications, oral cavity assessment, and targeted physical examination (extraoral, head and neck) during Screening
  5. Have a minimum of six unrestored bicuspids and molars with ≤50% of molars and bicuspids having restorations, crowns, sealants or are missing
  6. Demonstrated ability to expectorate ≥2mL of stimulated saliva in 5 minutes
  7. Have a salivary S. mutans of 1.0 x 10e5 CFUs/mL or greater at Screening using MSB agar plating
  8. Willing to refrain from using non-study dentifrice and other non-study oral care products (oral care rinses, fluoride products, etc.) during the study
  9. Willing to postpone elective dental procedures (e.g., dental cleanings) between Screening and final post-treatment visit
  10. Willing and able to comply with oral hygiene and diet instructions
  11. Has dentition adequate for custom dental tray gel application
  12. Able to understand and sign the Assent and/or Informed Consent Form prior to initiation of study procedures
  13. Able to communicate with the Investigator/study center personnel, understand and comply with the study requirements, and willing to return for protocol-specified visits at the appointed times

Exclusion Criteria:

  1. Advanced periodontal disease
  2. Active caries lesion(s) within 30 days prior to study drug administration (confirmed by comprehensive caries examination including standard radiographs); Note: Subjects presenting with insipient, non-cavitated lesion(s) are not excluded
  3. Medical condition (e.g., artificial heart valve, history of infective endocarditis, cardiac transplant with valvular dysfunction, congenital heart disease or total joint replacement) for which antibiotics are recommended prior to dental visits and/or procedures
  4. Pathologic lesions of the oral cavity
  5. Full or partial dentures, or orthodontic appliances, e.g., night guards, permanent retainers
  6. Use of systemic antibiotics, topical oral antibiotics, or use of other drugs, which in the opinion of the Investigator could influence the study outcome, within 30 days prior to Screening
  7. Medical history indicating the woman is pregnant, breastfeeding/ lactating or has a positive urine pregnancy test
  8. Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to study drug administration
  9. Prior participation in a C16G2 clinical trial and known to have received C16G2 active gel or mouth rinse
  10. Presence of any condition or concurrent illness, which in the opinion of the Investigator, would compromise normal immune function, interfere with the use of study dentifrice and oral care products, or interfere with the ability to comply with study requirements, or jeopardize the safety of the subject or the validity of the study results

Sites / Locations

  • Indiana University School of Dentistry
  • John F. Pittaway, DMD
  • New York University College of Dentistry
  • University of Pennsylvania School of Dental Medicine
  • Anthony Henegar, DDS, PA

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Adolescent Safety Only Cohort

Study Arm 1

Study Arm 2

Arm Description

Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.

Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.

Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.

Outcomes

Primary Outcome Measures

Safety of multiple C16G2 Gel administrations as measured by adverse events
Subjects will be monitored for adverse events throughout the study. At specified clinic visits a targeted physical exam and oral cavity assessment will be performed and vital signs will be taken.

Secondary Outcome Measures

Targeted antimicrobial activity of C16G2 Gel applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque
Total bacteria in saliva and dental plaque post-study drug administration

Full Information

First Posted
July 1, 2015
Last Updated
July 25, 2019
Sponsor
Armata Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02509845
Brief Title
Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects
Official Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Administered in Multiple Oral Gel Doses to Adolescent and Adult Dental Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Armata Pharmaceuticals, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.
Detailed Description
The purpose of the clinical study is to evaluate the safety and microbiology of C16G2 administered in multiple oral gel doses to adolescent and adult dental subjects. Subjects will be assigned to three study cohorts and receive 2 different volumes of C16G2 Gel or Placebo. Prior to commencing enrollment of subjects 12-17 years of age, a safety only cohort of 4-8 adolescent subjects will receive 4 study drug administrations on Day 0. A safety data review will be performed by the Medical Monitor on Days 1 and 5. If no safety concerns are identified, enrollment of adolescent subjects receiving 7 days of study drug administration will be initiated in Study Arms 1 & 2. Enrollment of adult subjects in Study Arms 1 & 2 may start before the Adolescent Safety Only Cohort is initiated. Before dosing of study drug, eligible subjects will undergo professional dental prophylaxis on Day 0. Microbiology will be assessed by measuring S. mutans and total bacteria counts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Caries

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adolescent Safety Only Cohort
Arm Type
Experimental
Arm Description
Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
Arm Title
Study Arm 1
Arm Type
Experimental
Arm Description
Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
Arm Title
Study Arm 2
Arm Type
Experimental
Arm Description
Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
Intervention Type
Drug
Intervention Name(s)
C16G2
Other Intervention Name(s)
Antimicrobial peptide
Intervention Description
Antimicrobial peptide
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Safety of multiple C16G2 Gel administrations as measured by adverse events
Description
Subjects will be monitored for adverse events throughout the study. At specified clinic visits a targeted physical exam and oral cavity assessment will be performed and vital signs will be taken.
Time Frame
Screening to week 41
Secondary Outcome Measure Information:
Title
Targeted antimicrobial activity of C16G2 Gel applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque
Time Frame
Microbiology assessments at screeninig, weeks 1, 2, 4, 8, 12, 13, 27, and 41
Title
Total bacteria in saliva and dental plaque post-study drug administration
Time Frame
Total bacteria at weeks 1, 2, 13, 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adolescent Safety Only Cohort: Males and females, 12-17 years of age, inclusive, at the time the Assent and Informed Consent Form is signed. Study Arms 1 & 2: Males and females, 12-75 years of age, inclusive, at the time the Assent and/or Informed Consent Form is signed Female subjects of childbearing potential, defined as not surgically sterile or at least two (2) years postmenopausal, must agree to use one of the following forms of contraception from screening through the last study visit: hormonal (oral, implant, or injection) begun >30 days prior to screening; barrier (condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive options may also include abstinence, relationship with same sex partner or partner who has had a vasectomy at least six (6) months prior to the screening visit Male subjects only: willing to use contraception or abstain from sexual activity beginning with the first exposure to study drug and continuing until discharged from the study due to completion or Early Termination Healthy, as determined by the Investigator, based on medical and dental history, concurrent illnesses, laboratory results, concomitant medications, oral cavity assessment, and targeted physical examination (extraoral, head and neck) during Screening Have a minimum of six unrestored bicuspids and molars with ≤50% of molars and bicuspids having restorations, crowns, sealants or are missing Demonstrated ability to expectorate ≥2mL of stimulated saliva in 5 minutes Have a salivary S. mutans of 1.0 x 10e5 CFUs/mL or greater at Screening using MSB agar plating Willing to refrain from using non-study dentifrice and other non-study oral care products (oral care rinses, fluoride products, etc.) during the study Willing to postpone elective dental procedures (e.g., dental cleanings) between Screening and final post-treatment visit Willing and able to comply with oral hygiene and diet instructions Has dentition adequate for custom dental tray gel application Able to understand and sign the Assent and/or Informed Consent Form prior to initiation of study procedures Able to communicate with the Investigator/study center personnel, understand and comply with the study requirements, and willing to return for protocol-specified visits at the appointed times Exclusion Criteria: Advanced periodontal disease Active caries lesion(s) within 30 days prior to study drug administration (confirmed by comprehensive caries examination including standard radiographs); Note: Subjects presenting with insipient, non-cavitated lesion(s) are not excluded Medical condition (e.g., artificial heart valve, history of infective endocarditis, cardiac transplant with valvular dysfunction, congenital heart disease or total joint replacement) for which antibiotics are recommended prior to dental visits and/or procedures Pathologic lesions of the oral cavity Full or partial dentures, or orthodontic appliances, e.g., night guards, permanent retainers Use of systemic antibiotics, topical oral antibiotics, or use of other drugs, which in the opinion of the Investigator could influence the study outcome, within 30 days prior to Screening Medical history indicating the woman is pregnant, breastfeeding/ lactating or has a positive urine pregnancy test Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to study drug administration Prior participation in a C16G2 clinical trial and known to have received C16G2 active gel or mouth rinse Presence of any condition or concurrent illness, which in the opinion of the Investigator, would compromise normal immune function, interfere with the use of study dentifrice and oral care products, or interfere with the ability to comply with study requirements, or jeopardize the safety of the subject or the validity of the study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Wolff, MD
Organizational Affiliation
New York University, School of Dentistry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University School of Dentistry
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
John F. Pittaway, DMD
City
Kalispell
State/Province
Montana
ZIP/Postal Code
59901
Country
United States
Facility Name
New York University College of Dentistry
City
New York
State/Province
New York
ZIP/Postal Code
10010
Country
United States
Facility Name
University of Pennsylvania School of Dental Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Anthony Henegar, DDS, PA
City
Irving
State/Province
Texas
ZIP/Postal Code
75063
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

We'll reach out to this number within 24 hrs